
Rochelle Bagatell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5138495/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 985-993.	1.5	285
2	Mechanisms of neuroblastoma regression. Nature Reviews Clinical Oncology, 2014, 11, 704-713.	27.6	228
3	lrinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	10.7	205
4	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
5	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. Journal of Clinical Oncology, 2011, 29, 208-213.	1.6	127
6	Historical time to disease progression and progressionâ€free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group earlyâ€phase trials. Cancer, 2017, 123, 4914-4923.	4.1	108
7	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	1.6	98
8	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
9	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	7.0	95
10	Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study. Pediatric Blood and Cancer, 2014, 61, 833-839.	1.5	87
11	Clinical utility of custom-designed NGS panel testing in pediatric tumors. Genome Medicine, 2019, 11, 32.	8.2	79
12	Neuroblastoma. Pediatric Blood and Cancer, 2021, 68, e28473.	1.5	59
13	Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). European Journal of Cancer, 2019, 112, 66-79.	2.8	49
14	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 1537-1543.	1.6	47
15	Genetic discoveries and treatment advances in neuroblastoma. Current Opinion in Pediatrics, 2016, 28, 19-25.	2.0	44
16	The challenge of defining "ultraâ€highâ€risk―neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556	. 1.5	43
17	Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. Journal of Molecular Diagnostics, 2019, 21, 873-883.	2.8	41
18	Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study. Journal of Clinical Oncology, 2016, 34, 740-746.	1.6	37

#	Article	IF	CITATIONS
19	Unrealistic parental expectations for cure in poorâ€prognosis childhood cancer. Cancer, 2020, 126, 416-424.	4.1	34
20	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. Journal of the National Cancer Institute, 2021, 113, 282-291.	6.3	33
21	Diagnosis of Beckwith–Wiedemann syndrome in children presenting with Wilms tumor. Pediatric Blood and Cancer, 2018, 65, e27296.	1.5	32
22	Using electronic medical record data to report laboratory adverse events. British Journal of Haematology, 2017, 177, 283-286.	2.5	31
23	Likelihood of Bone Recurrence in Prior Sites of Metastasis in Patients With High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 839-845.	0.8	30
24	VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26728.	1.5	30
25	The ganglioside G _{D2} as a circulating tumor biomarker for neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28031.	1.5	30
26	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. American Journal of Hematology, 2017, 92, 141-148.	4.1	29
27	Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study Journal of Clinical Oncology, 2012, 30, 9500-9500.	1.6	29
28	Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin. Oncologist, 2018, 23, 762-e79.	3.7	28
29	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Journal of Pain and Symptom Management, 2020, 60, 782-789.	1.2	27
30	Advances in neuroblastoma therapy. Current Opinion in Pediatrics, 2019, 31, 14-20.	2.0	25
31	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. JAMA Pediatrics, 2014, 168, 925.	6.2	24
32	Suspected posaconazole toxicity in a pediatric oncology patient. Pediatric Blood and Cancer, 2015, 62, 1682-1682.	1.5	24
33	Proton therapy for pediatric head and neck malignancies. Pediatric Blood and Cancer, 2018, 65, e26858.	1.5	24
34	Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1775-1781.	1.5	21
35	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 270-277.	0.8	20
36	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 401-408.	0.8	19

#	Article	IF	CITATIONS
37	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Medicine, 2015, 4, 1356-1364.	2.8	17
38	A safety and feasibility trial of ¹³¹ lâ€MIBG in newly diagnosed highâ€risk neuroblastoma: A Children's Oncology Group study. Pediatric Blood and Cancer, 2021, 68, e29117.	1.5	17
39	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS ONE, 2015, 10, e0143480.	2.5	16
40	Establishing a highâ€risk neuroblastoma cohort using the pediatric health information system database. Pediatric Blood and Cancer, 2014, 61, 1129-1131.	1.5	15
41	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	1.2	14
42	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalinâ€Fixed Paraffinâ€Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	1.5	13
43	Comparison of administrative/billing data to expected protocolâ€mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1184-1189.	1.5	12
44	Sclerosing Epithelioid Fibrosarcoma of the Bone With Rare EWSR1-CREB3L3 Translocation Driving Upregulation of the PI3K/mTOR Signaling Pathway. Pediatric and Developmental Pathology, 2019, 22, 594-598.	1.0	12
45	Outcomes among pediatric patients with cancer who are treated on trial versus off trial: A matched cohort study. Cancer, 2020, 126, 3471-3482.	4.1	12
46	Volume–Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 404-410.e1.	0.4	11
47	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	1.6	11
48	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. Pediatric Critical Care Medicine, 2018, 19, e312-e320.	0.5	10
49	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Pediatric Blood and Cancer, 2016, 63, 901-907.	1.5	8
50	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. Cancer, 2016, 122, 3394-3400.	4.1	8
51	Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precision Oncology, 2021, 5, 1840-1852.	3.0	8
52	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group Journal of Clinical Oncology, 2022, 40, 10003-10003.	1.6	6
53	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. PLoS ONE, 2016, 11, e0151362.	2.5	5
54	Efficacy of postâ€induction therapy for highâ€risk neuroblastoma patients with endâ€induction residual disease. Cancer, 2022, 128, 2967-2977.	4.1	5

#	Article	IF	CITATIONS
55	A Rapid Progression of Disease After Surgical Excision of a Malignant Rhabdoid Tumor of the Bladder. Urology, 2015, 85, 664-666.	1.0	4
56	Early discharge as a mediator of greater <scp>ICU</scp> â€level care requirements in patients not enrolled on the <scp>AAML</scp> 0531 clinical trial: a Children's Oncology Group report. Cancer Medicine, 2016, 5, 2412-2416.	2.8	4
57	The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma?. Journal of Clinical Oncology, 2016, 34, 2437-2439.	1.6	4
58	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2017, 102, e340-e343.	3.5	4
59	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in highâ€risk neuroblastoma using a national administrative database. Pediatric Blood and Cancer, 2018, 65, e27372.	1.5	4
60	Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials. Journal of Clinical Oncology, 2021, 39, 2525-2527.	1.6	4
61	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children's Oncology Group (COG) Journal of Clinical Oncology, 2016. 34. 10502-10502.	1.6	4
62	Tandem Transplant for High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 729.	7.4	3
63	Role of Metastatic Site Irradiation in Pediatric Patients With Metastatic Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2020, 42, e305-e309.	0.6	3
64	A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma. Cancer Chemotherapy and Pharmacology, 2021, 87, 807-815.	2.3	3
65	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatric Blood and Cancer, 2021, 68, e29282.	1.5	3
66	Historical gold standard for time-to-progression (TTP) and progression-free survival (PFS) from relapsed/refractory neuroblastoma modern era (2002-2014) patients Journal of Clinical Oncology, 2014, 32, 10034-10034.	1.6	3
67	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data Journal of Clinical Oncology, 2014, 32, 10069-10069.	1.6	3
68	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
69	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG) Journal of Clinical Oncology, 2018, 36, 10508-10508.	1.6	3
70	Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study Journal of Clinical Oncology, 2021, 39, 10005-10005.	1.6	2
71	G _{D2} as a circulating tumor biomarker (CTB) for neuroblastoma (NBL) Journal of Clinical Oncology, 2018, 36, 10538-10538.	1.6	2
72	Refining megatherapy, improving outcome in neuroblastoma. Lancet Oncology, The, 2017, 18, 423-424.	10.7	1

#	Article	IF	CITATIONS
73	Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: ÂA Children's Oncology Group study Journal of Clinical Oncology, 2012, 30, 9540-9540.	1.6	1
74	Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors Journal of Clinical Oncology, 2014, 32, 10052-10052.	1.6	1
75	Poverty and survival in targeted immunotherapy clinical trials Journal of Clinical Oncology, 2019, 37, 10034-10034.	1.6	1
76	Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States. Blood, 2012, 120, 4278-4278.	1.4	1
77	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	1.4	1
78	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1 Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
79	Clinical significance of serial tumor next generation sequencing (NGS) in 155 pediatric cancer patients Journal of Clinical Oncology, 2020, 38, e13666-e13666.	1.6	1
80	More Than Meets the Eye? A Cautionary Tale of Malignant Ectomesenchymoma Treated as Low-risk Orbital Rhabdomyosarcoma. Journal of Pediatric Hematology/Oncology, 2021, 43, e854-e858.	0.6	1
81	Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy Journal of Clinical Oncology, 2022, 40, 10025-10025.	1.6	1
82	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
83	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. children's hospitals Journal of Clinical Oncology, 2014, 32, 6598-6598.	1.6	0
84	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group Journal of Clinical Oncology, 2014, 32, 7086-7086.	1.6	0
85	Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2653-2653.	1.4	0
86	ÂResource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
87	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB) Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
88	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
89	Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium Journal of Clinical Oncology, 2016, 34, 10556-10556.	1.6	0
90	Effect of infusion duration on high-dose methotrexate (HDMTX) acute kidney injury (AKI) Journal of Clinical Oncology, 2017, 35, e22013-e22013.	1.6	0

#	Article	IF	CITATIONS
91	Predictors of differential response to induction chemotherapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG) Journal of Clinical Oncology, 2018, 36, 10532-10532.	1.6	0
92	Using administrative laboratory result data to describe adverse events Journal of Clinical Oncology, 2018, 36, e18698-e18698.	1.6	0
93	Outcome in patients with refractory high-risk neuroblastoma Journal of Clinical Oncology, 2020, 38, 10537-10537.	1.6	0
94	Trends in conditional survival and predictors of late death in neuroblastoma Journal of Clinical Oncology, 2020, 38, 10533-10533.	1.6	0
95	Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children's Oncology Group (COG) ANBL0032 Journal of Clinical Oncology, 2020, 38, 10523-10523.	1.6	0
96	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children's Oncology Group Journal of Clinical Oncology, 2022, 40, 10027-10027.	1.6	0
97	Predictors of differential outcomes according to response to induction chemotherapy in high-risk neuroblastoma Journal of Clinical Oncology, 2022, 40, 10032-10032.	1.6	0
98	Racial, ethnic, and socioeconomic survival disparities among children with high-risk neuroblastoma treated on upfront Children's Oncology Group clinical trials Journal of Clinical Oncology, 2022, 40, 10005-10005.	1.6	0
99	Patterns of relapse after immunotherapy in patients with high-risk neuroblastoma Journal of Clinical Oncology, 2022, 40, 10043-10043.	1.6	0